

### **Global Equity Research**

#### Americas

Electric Utilities

Sector Comment

# No. 5

#### Gov. Brown names fifth and final commissioner to CPUC

Mark Ferron, the former COO of Deutsche Bank's Global Markets Division, was named as the fifth CPUC commissioner yesterday. Mr. Ferron's appointment fills the one remaining chair left to be filled by Gov. Brown. According to press reports, Ferron is well-known within Democratic circles in the Bay Area and the State, but is largely unknown elsewhere.

#### What does Mark Ferron bring to the table?

**UBS Investment Research** 

**US Electric Utilities & IPPs** 

We think Gov. Brown has carefully selected a commission comprised of balance: President Peevey's background includes a respected track record in labor law and as a corporate executive (at EIX) while Simon's expertise is natural gas, infrastructure, and investments. Recent CPUC appointees Florio and Sandoval added consumer advocacy and telecommunications insight. And finally, Mark Ferron brings capital markets expertise. In the glass is half full category, Ferron should provide a voice of reason that understands where the tipping point is between investment appeal and consumer interests.

### For now, PCG rate case still on tomorrows agenda

As of 4 pm (ET), PCG's pending general rate case remained on the agenda for a decision during tomorrows CPUC meeting. While the proposed and alternate decisions were largely supportive of PCG's negotiated settlement, which should suggest a smoother commission decision, we would not be surprised if a decision in the case was postponed to a subsequent meeting.

23 March 2011

www.ubs.com/investmentresearch

Jim von Riesemann Analyst jim.vonriesemann@ubs.com +1-212-713-4260

Julien Dumoulin-Smith Analyst julien.dumoulin-smith@ubs.com +1 212 -713 9848

> Aileen Long Associate Analyst aileen.long@ubs.com +1 212 713 3475

This report has been prepared by UBS Securities LLC ANALYST CERTIFICATION AND REQUIRED DISCLOSURES BEGIN ON PAGE 2. UBS does and seeks to do husiness with companies covered in its research reports. As a

UBS does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

#### Statement of Risk

Risks for Utilities and Independent Power Producers (IPPs) primarily relate to volatile commodity prices for power, natural gas, and coal. Risks to IPPs also stem from load variability, and operational risk in running these facilities. Rising coal and, to a certain extent, uranium prices could pressure margins as the fuel hedges roll off Competitive Integrateds. Further, IPPs face declining revenues as in the money power and gas hedges roll off. Other non-regulated risks include weather and for some, foreign currency risk, which again must be diligently accounted in the company's risk management operations. Major external factors, which affect our valuation, are environmental risks. Environmental capex could escalate if stricter emission standards are implemented. We believe a nuclear accident or a change in the Nuclear Regulatory Commission/Environment Protection Agency regulations could have a negative impact on our estimates.

Risks for regulated utilities include the uncertainty around the composition of state regulatory Commissions, adverse regulatory changes, unfavorable weather conditions, variance from normal population growth, and changes in customer mix. Changes in macroeconomic factors will affect customer additions/subtractionsand usage patterns

#### Analyst Certification

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, including with respect to UBS, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

## Required Disclosures

This report has been prepared by UBS Securities LLC, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical performance information; and certain additional disclosures concerning UBS research recommendations, please visit www.ubs.com/disclosures. The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy businesses by the China Securities Regulatory Commission.

UBS 12-Month Rating	Rating Category	Coverage <sup>1</sup>	IB Services <sup>2</sup>
Buy	Buy	49%	40%
Neutral	Hold/Neutrai	42%	35%
Sell	Sell	8%	21%
UBS Short-Term Rating	Rating Category	Coverage <sup>3</sup>	IB Services <sup>4</sup>
Buy	Buy	less than 1%	14%
Sell	Sell	less than 1%	0%

#### UBS Investment Research: Global Equity Rating Allocations

1:Percentage of companies under coverage globally within the 12-month rating category.

2:Percentage of companies within the 12-month rating category for which investment banking (IB) services were provided within the past 12 months.

3:Percentage of companies under coverage globally within the Short-Term rating category.

4:Percentage of companies within the Short-Term rating category for which investment banking (IB) services were provided within the past 12 months.

Source: UBS. Rating allocations are as of 31 December 2010.

UBS Investment Research: Global Equity Rating Definitions

UBS 12-Month Rating	Definition	
Buy	FSR is > 6% above the MRA.	
Neutral	FSR is between -6% and 6% of the MRA.	
Sell	FSR is > 6% below the MRA.	
UBS Short-Term Rating	Definition	
Buy	Buy: Stock price expected to rise within three months from the time the rating was assigned because of a specific catalyst or event.	
Sell	Sell: Stock price expected to fall within three months from the time the rating was assigned because of a specific catalyst or event.	

#### **KEY DEFINITIONS**

Forecast Stock Return (FSR) is defined as expected percentage price appreciation plus gross dividend yield over the next 12 months.

**Market Return Assumption (MRA)** is defined as the one-year local market interest rate plus 5% (a proxy for, and not a forecast of, the equity risk premium).

**Under Review (UR)** Stocks may be flagged as UR by the analyst, indicating that the stock's price target and/or rating are subject to possible change in the near term, usually in response to an event that may affect the investment case or valuation. **Short-Term Ratings** reflect the expected near-term (up to three months) performance of the stock and do not reflect any change in the fundamental view or investment case.

Equity Price Targets have an investment horizon of 12 months.

#### **EXCEPTIONS AND SPECIAL CASES**

**UK and European Investment Fund ratings and definitions are:** Buy: Positive on factors such as structure, management, performance record, discount; Neutral: Neutral on factors such as structure, management, performance record, discount; Sell: Negative on factors such as structure, management, performance record, discount.

**Core Banding Exceptions (CBE):** Exceptions to the standard +/-6% bands may be granted by the Investment Review Committee (IRC). Factors considered by the IRC include the stock's volatility and the credit spread of the respective company's debt. As a result, stocks deemed to be very high or low risk may be subject to higher or lower bands as they relate to the rating. When such exceptions apply, they will be identified in the Company Disclosures table in the relevant research piece.

Research analysts contributing to this report who are employed by any non-US affiliate of UBS Securities LLC are not registered/qualified as research analysts with the NASD and NYSE and therefore are not subject to the restrictions contained in the NASD and NYSE rules on communications with a subject company, public appearances, and trading securities held by a research analyst account. The name of each affiliate and analyst employed by that affiliate contributing to this report, if any, follows.

UBS Securities LLC: Jim von Riesemann; Julien Dumoulin-Smith; Aileen Long.

Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report.

#### **Global Disclaimer**

This report has been prepared by UBS Securities LLC, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS. In certain countries, UBS AG is referred to as UBS SA

This report is for distribution only under such circumstances as may be permitted by applicable law. Nothing in this report constitutes a representation that any investment strategy or Inis report is for distribution only under such circumstances as may be permitted by applicable law. Nothing in this report constitutes a representation that any investment strategy or recommendation contained herein is suitable or appropriate to a recipient's individual circumstances or otherwise constitutes a personal recommendation. It is published solely for information purposes, it does not constitute an advertisement and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments in any jurisdiction. No representation or warranty, either express or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein, except with respect to information concerning UBS AG, its subsidiaries and affiliates, nor is it intended to be a complete statement or summary of the securities, markets or developments referred to in the report. UBS does not undertake that investors will obtain profits, nor will it share with investors any investment profits nor accept any liability for any investment losses. Investments involve risks and investors should exercise prudence in making their investment decisions. The report should not be regarded by recipients as a substitute for the exercise of their own judgement. Past performance is not necessarily a guide to future performance. The value of any investment or income may go down as well as up and you may not get back the full amount invested. Any opinions expressed in this report are subject to change without notice and may differ or be contrary to opinions expressed by other business areas or groups of UBS as a result of using different assumptions and criteria. Research will initiate, update and cease coverage solely at the discretion of UBS Investment Bank Research Management. The analysis contained herein is based on numerous assumptions The sector will initiate, update and cease coverage solely at the discretion of USS investment bank research will adgement. The analysis contained herein is based on numerous assumptions, Different assumptions could result in materially different results. The analysis (5) responsible for the preparation of this report may interact with trading desk personnel, sales personnel and other constituencies for the purpose of gathering, synthesizing and interpreting market information. UBS is under no obligation to update or keep current the information contained herein. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS, into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this report is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues, however, compensation may relate to the revenues of UBS Investment Bank as a whole, of which investment banking, sales and trading are a part.

The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates and other market conditions. Past performance is not necessarily indicative of future exuits. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument mentioned in this report. For investment advice, trade execution or other enquines, clients should contact their local sales representative. Neither UBS nor any of this affiliates, directors, employees or agents accepts any liability for any loss or damage arising out of the use of all or any part of this report. For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC and/or UBS Capital Markets LP) acts as a market maker or liquidity provider (in accordance with the laws and regulation of any other EU jurisdictions, such information is separately disclosed in this research report. UBS and its affiliates, and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein.

Any prices stated in this report are for information purposes only and do not represent valuations for individual securities or other instruments. There is no representation that any transaction can or could have been effected at those prices and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions, by UBS or any other source, may yield substantially different results.

can or could have been effected at those prices and any prices do not necessarily reflect USS internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions, by UBS or any other source, may yield substantially different results. United Kingdom and the rest of Europe: Except as otherwise specified herein, this material is communicated by UBS Limited, a subsidiary of UBS AG, to persons who are eligible counterparties or professional clients and is only available to such persons. The information contained herein does not apply to, and should not be relied upon by, retail clients. UBS Limited is authorised and regulated by the Financial Services Authority (FSA). UBS research compiles with all the FSA requirements and laws concerning discosures and these are indicated on the research where applicable. France: Prepared by UBS Limited and distributed by UBS contribes france SA. As Germany: Prepared by UBS Limited and distributed by UBS scurities France SA. Germany: Prepared by UBS Limited and distributed by UBS scurities France SA. Germany: Prepared by UBS Limited and distributed by UBS scurities France SA. So is regulated by the Suncessantial fur Finanzotienstelistungsaufsicht (BaFin). Spain: Prepared by UBS Limited and UBS becurities CJSC. So is regulated by the Sand distributed by UBS sciences CONMV). Turkey: Prepared by UBS Limited and UBS board investors only. Haly: Prepared by UBS Limited and UBS Italia Sim S.p.A. As contributed to this report, the report is also deemed to have been prepared by UBS Limited. Science (PMV) Limited (Registration No. 1995/01114007) is a member of the JSE Limited, the So that frica (Pty) Limited (Registration No. 1995/0114007) is a member of the JSE Limited, the south Africa (Pty) Limited (Registration No. 1995/0114007) is a member of the JSE Scientifes Science is also deemed to have been prepared by UBS Scientifies Context of the pricipal Canadia stributed to US Securities CLC or US Financial Services Inc. accepts res to from the to the by affiliates of USS Securities Pie. Ltd., 2/F,2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000 SEBI Registration Numbers: NSE (Capital Market Segment): INB230951431, NSE (F&O Segment) INF230951431, BSE (Capital Market Segment) INB010951437.

The disclosures contained in research reports produced by UBS Limited shall be governed by and construed in accordance with English law

UBS specifically prohibits the redistribution of this material in whole or in part without the written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect. Images may depict objects or elements which are protected by third party copyright, trademarks and other intellectual property rights. © UBS 2011. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights rese